Results 121 to 130 of about 46,203 (306)

NFAT2 is a critical regulator of the anergic phenotype in chronic lymphocytic leukaemia

Nature Communications, 2017
NFAT2 is a transcription factor that has been linked with chronic lymphocytic leukaemia (CLL), but its functions in CLL manifestation are still unclear.
Melanie Märklin, Jonas S. Heitmann, Alexander R. Fuchs, Felicia M. Truckenmüller, Michael Gutknecht, Stefanie Bugl, Sebastian J. Saur, Juliane Lazarus, Ursula Kohlhofer, Leticia Quintanilla-Martinez, Hans-Georg Rammensee, Helmut R. Salih, Hans-Georg Kopp, Michael Haap, Andreas Kirschniak, Lothar Kanz, Anjana Rao, Stefan Wirths, Martin R. Müller   +18 more
doaj   +1 more source

Effect of developmental changes on pharmacokinetics of drugs used in the treatment of infant acute lymphoblastic leukaemia—A comprehensive review

British Journal of Clinical Pharmacology, EarlyView.
While the event‐free survival (EFS) of children treated for acute lymphoblastic leukaemia (ALL) has improved greatly in the last decades, the EFS for patients diagnosed with ALL before the age of one is still under 50%. This outcome further decreases when infants have a rearrangement in the gene encoding histone‐lysine N‐methyltransferase 2A (KMT2A ...
Tirsa de Kluis, Leiah J. Brigitha, Lidwien M. Hanff, Alwin D. R. Huitema, Inge M. van der Sluis, Meta H. M. Diekstra   +5 more
wiley   +1 more source

Functional interaction between CD180 Toll-like receptor (TLR) and B cell receptor (BCR) in the biology of Chronic Lymphocytic Leukaemia (CLL) [PDF]

, 2017
Chronic Lymphocytic Leukaemia (CLL) is the most common leukaemia in the western world and remains incurable. It is driven by as yet unknown (auto)antigens via the B cell receptor (BCR) and growth, survival and expansion signals it receives from the ...
Rajakaruna, A., Rajakaruna, A.
core  

Cold atmospheric plasma‐mediated tumor microenvironment remodeling for cancer treatment

BMEMat, EarlyView.
Schematic presentation of CAP‐mediated TME remodeling. This review summarizes recent efforts in cold atmospheric plasma (CAP) application in cancer treatment, highlighting the anticancer potential of CAP, molecular mechanisms, and future perspectives for further improvement and clinical translation.
Israr Khan, Qiujie Fang, Cao Fei, Ziyuan Wang, Zhaowei Chen, Guojun Chen, Zhiming Xu, Shu Xu, Zhitong Chen   +8 more
wiley   +1 more source

Nanomaterials‐mediated glycolysis rewriting to potentiate tumor immunotherapy

BMEMat, EarlyView.
This review systematically summarizes cutting‐edge advances in glycolysis‐rewiring nanomedicines, emphasizing their mechanisms in reversing immunosuppression and reinvigorating antitumor immune responses. Challenges in clinical translation and future directions for designing multifunctional metabolic‐immune modulators are also critically discussed ...
Zilin Ma, Songyan Li, Jie Yan, Xuechun Wang, Wen Zhao, Yunxuan Song, Dongdong Liu, Jianwei Jiao, Xiuying Duan, Guiqiang Zhang   +9 more
wiley   +1 more source

Dynamics of natural killer cell function upon recurrent stimulation

Biotechnology Progress, EarlyView.
Weekly stimulation of peripheral blood‐derived NK cells with engineered K562 feeder cells resulted in two distinct growth phases, shifting around Day 21–26. Cells in growth phase 2 exhibited slower growth, reduced metabolic activity, and lower cytotoxicity than cells from growth phase 1, which has implications for NK cell biomanufacturing.
Jennifer One, Janani Narayan, Frank Cichocki, Wei‐Shou Hu, Samira M. Azarin   +4 more
wiley   +1 more source

Monodentate Phosphine Modulation in Cyclometallated Platinum(II) Complexes for Antileishmanial, Antiviral, and Antitumor Applications

ChemMedChem, EarlyView.
Schematic representation depicting the influence of phosphine ligand identity on the biological and physicochemical characteristics of Pt(II) complexes: PTA promotes antileishmanial activity, PPh2(Php–COOH) strengthens antiviral activity, and TCEP enhances fluorescence.
Antonio A. de Oliveira‐Neto, Gustavo Clauss, Jennyfer Castro, Marcus S. A. Garcia, Natasha M. Cassani, Bruna C. Sandim, Ana Laura C. Oliveira, Stephanie P. B. Reyes, Nádija N. P. da Silva, Fillipe V. Rocha, Ana C. G. Jardim, Danilo C. Miguel, Camilla Abbehausen   +12 more
wiley   +1 more source

Immune failure, infection and survival in chronic lymphocytic leukemia

Haematologica, 2018
Kyle R. Crassini, O. Giles Best, Stephen P. Mulligan   +2 more
doaj   +1 more source

Clinical assessment of mocravimod as a victim of drug–drug interactions via CYP3A4 metabolism and transporters

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Mocravimod, a novel immunomodulator targeting sphingosine‐1‐phosphate receptor (S1PR), is being developed as a maintenance treatment for patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation. Preclinical data suggested that cytochrome (CYP) 3A4 is the primary enzyme involved in mocravimod metabolism.
Dymphy R. Huntjens, Stephan Oehen, Elisabeth Kueenburg   +2 more
wiley   +1 more source

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2025 Update

Clinical Pharmacology &Therapeutics, EarlyView.
Thiopurine methyltransferase (TPMT) and Nudix hydrolase 15 (NUDT15) are key enzymes that catabolize thiopurines. Decreased or no‐function alleles in TPMT and NUDT15 are associated with reduced or no enzyme activity and predictive of pronounced adverse effects, including severe myelosuppression, that may occur among individuals treated with standard ...
Maud Maillard, Matthias Schwab, Michelle Whirl‐Carrillo, Ann M. Moyer, Guilherme Suarez‐Kurtz, Ching‐Hon Pui, C. Michael Stein, Teri E. Klein, Claire Spahn, Sooyeon Kwon, Juanda Leo Hartono, Nanne K. de Boer, Tariq Ahmad, Federico Guillermo Antillon‐Klussmann, Kelly E. Caudle, Motohiro Kato, Allen E. J. Yeoh, Kjeld Schmiegelow, Jun J. Yang   +18 more
wiley   +1 more source